EGFR and neoplasm: First-generation EGFR inhibitors (e.g., gefitinib and erlotinib) have shown increased objective response (ORRs) and progression-free survival (PFS) compared to conventional cytotoxic treatment of patients suffering from EGFR-mutated tumours [73,76].